

- Rotavirus vaccine, 1289
 Roth's spots, 40e-4, 200, 201f
 Rotigotine, 2615, 2616t
 Rotor syndrome, 282, 2003t, 2004
 Rouleaux formation, 81e-1, 81e-3f
 Round pneumonia, 951
 Roundworms, 255e-1. *See also* Nematodes/
 nematode infections
Rousettus aegyptiacus, 1324
 Rous sarcoma virus, 101e-2, 225e-1t
 Roux-en-Y gastric bypass, 2398, 2398f, 2434
 Rowasa enemas, 1960
 RPE65 gene, 91e-3
 RPR (rapid plasma reagin) test, 1137, 1137f
 16S rRNA genes, bacterial, 86e-2-4
 18S rRNA genes, eukaryotic, 86e-4
 RSDL (reactive skin decontamination lotion),
 262e-6
 RSPO1 gene mutations, 2356t
 RSV infections. *See* Human respiratory syncytial
 virus (HRSV) infections
 rT₃ (reverse T₃), 2283f
 RTA. *See* Renal tubular acidosis (RTA)
 RTH (resistance to thyroid hormone), 435,
 2286t, 2287
 rtPA (recombinant tissue plasminogen activator).
See Alteplase (rtPA)
 RT-PCR (reverse transcriptase polymerase chain
 reaction), 1247, 1247t
 "Rubber person" syndrome, 2510
 Rubella (German measles), 230e-1
 clinical features of, 128t, 230e-1, 362
 oral, 236
 skin, 25e-2f, 127, 128t, 230e-1f, 362, 362t
 congenital, 50, 230e-1, 230e-2, 230e-2t, 785t,
 900, 1525
 diagnosis of, 230e-1-2, 1190t
 epidemiology of, 230e-1
 global considerations in, 230e-1, 230e-2-3,
 230e-3f
 incidence pre- and postvaccine, U.S., 785t
 pathogenesis of, 230e-1
 in pregnancy, 50, 127, 230e-2
 prevention of, 230e-2-3
 treatment of, 230e-2
 Rubella vaccine, 50, 230e-2-3, 230e-3f. *See*
also Measles-mumps-rubella vaccine
 (MMR)
 Rubella virus, 230e-1
 Rubeola. *See* Measles (rubeola)
 Rubidium-82, 270e-3, 270e-3t
 Rubinstein-Taybi syndrome, 431t
 Rubivirus, 230e-1. *See also* Rubella (German
 measles)
 Rubor, 414f, 1643, 1753
 Rubrospinal pathway, 155f
 Rufinamide, 2555t
 Rumination, 256, 1901
 Rumination disorder/syndrome, 259, 2719
 RUNX1 gene mutations, 135e-6, 680, 680t
 Runx2, 2455
 Russell body gastritis, 1932
 Russell-Silver syndrome, 83e-7
 Russell's viper bite, 2734, 2734f, 2738. *See also*
 Snakebites
 Russell venom viper test, 2131
 Ruxolitinib
 action of, 102e-5t, 103e-19
 adverse effects of, 674, 676
 for polycythemia vera, 674
 for primary myelofibrosis, 676
 RV (residual volume), 306e-1f, 306e-2, 306e-2f,
 306e-5f
 R value, 2023
 R wave, 269e-5f, 1451
 Ryanodine receptor, 40-41
 RYR1 gene, 462e-12
 RYR3 gene, 1241, 1241t
- S**
 S-100 protein, in carcinoma of unknown
 primary, 120e-2t
 Saaremaa virus, 1307t
 Sabia virus, 1306t
 Saccades, 197
 Saccadomania, 211
 Saccharomyces boulardii, 860, 860t
 Saccharopinuria, 434e-3t
 Sacular aneurysm
 aortic, 1637, 1638. *See also* Aortic aneurysm
 cerebral, 1784-1785. *See also* Subarachnoid
 hemorrhage
 Sacral agenesis, 48
 Sacral insufficiency fracture, 441e-33f
 Sacral pain, 118
 Sacral spinal lesions, 2651-2652
 Sacroiliitis
 in ankylosing spondylitis, 2169, 2171, 2172f
 in IBD, 1958
 in reactive arthritis, 2174, 2175
 SACT (sinoatrial conduction time), 1469
 Saddle-nose deformity
 in granulomatosis with polyangiitis, 1443,
 2183
 in relapsing polychondritis, 1443, 2203, 2203f
 Safety in health care, 12e-1
 in developing countries, 12e-1
 factors that increase likelihood of errors,
 12e-1
 frequency of adverse events, 12e-1-2
 measurement of, 12e-2
 national picture, 12e-2
 prevention of adverse events, 12e-2
 systems theory and, 12e-1, 12e-1f
 Safety theory, 12e-1
 Sagging brain syndrome, 2607
 St. John's wort, 14e-4, 42, 42t, 44, 389t
 St. Louis encephalitis virus, 1307t, 1315
 St. Vitus' dance. *See* Sydenham's chorea
 Salary compensation plan, 21
 Salicylates
 adverse effects of, 319, 324, 2130t
 drug interactions of, 42t, 103e-14
 overdose/poisoning with, 319, 473e-12t
 for rheumatic fever, 2152-2153
 for SLE, 2130t
 therapeutic monitoring of, 319
 Salicylic acid
 for acne vulgaris, 352
 for prickly heat, 479e-1
 for scabies, 2745
 for tinea versicolor, 350
 for warts, 351
 Saline
 half-normal, for hypovolemia, 298
 hypertonic, 302, 303, 309, 1780t
 hypotonic, 304
 isotonic, 298, 302, 2735
 normal
 for hyperkalemia, 312
 for hyponatremia, 301
 for hypovolemia, 298
 for sepsis/septic shock, 1757
 for SIADH, 610
 Saline infusion test, 1749, 2319
 Saliva
 artificial, 216
 characteristics of, 239
 HIV transmission via, 1223
 volume and electrolyte content of, 98e-4t
 Salivary duct obstruction, 241
 Salivary gland(s)
 benign tumors of, 503, 506
 diseases of, 239, 241
 enlargement of, 2167, 2167t
 IgG-4 related lesions of, 391e-1t, 391e-2,
 391e-2f
 malignant tumors of, 241, 503, 506
 Salivary stone (sialolithiasis), 46e-5f, 241
 Saliva substitutes, 241
 Salmeterol, 205e-3, 1705
 Salmonella spp.
 antibiotic resistance in, 941t, 1052, 1053, 1054
 chronic carriage of, 1052
 intercellular survival of, 145e-7
 laboratory identification of, 150e-2t
 subspecies/serotypes, 1049
Salmonella enteritidis, 1053
Salmonella spp. infections, 1049. *See also* Enteric
 (typhoid) fever
 antibiotic resistance in, 1053, 1054
 aortitis, 1642
 bacteremia, 1054
 bone, joint, and soft tissue, 1054
 in cancer patient, 486t
 CNS, 1054
 diagnosis of, 150e-2, 856, 1054
 endovascular, 1054
 epidemiology of, 1053
 food-related, 266
 gastroenteritis
 vs. appendicitis, 1987
 clinical features of, 266, 266t, 856t, 1053
 vs. IBD, 1956
 pathogenesis of, 1050
 treatment of, 857, 857t, 1054-1055, 1054t
 genital, 1054
 in HIV infection, 1252t, 1256-1257
 intraabdominal, 1054
 prevention and control of, 1055
 pulmonary, 1054
 in returned traveler, 802t
 splenic abscess, 851
 treatment of, 940t, 1054-1055, 1054t
 urinary tract, 1054
Salmonella typhi. *See also* Enteric (typhoid)
 fever
 as bioterrorism agent, 261e-9
 host receptors for, 145e-3
 multidrug-resistance in, 1050
 pathogenesis of, 1049
 Salmonellosis, nontyphoidal. *See* *Salmonella* spp.
 infections
 Salmon River virus, 1306t
 Salp15, 1150
 Salpingitis
 abdominal pain in, 106t, 107, 877
C. trachomatis, 1169, 1170t
 clinical features of, 877
 diagnosis of, 877
 Salpingo-oophorectomy, 593, 594, 597
 Salsalate, 2232t
 Salt-depletion heat exhaustion, 479e-2
 Salt therapy
 for metabolic alkalosis, 322
 for SIAD, 302
 for syncope, 145
 Salt-wasting disorders, 295, 299, 1612-1613
 Salt-wasting 21-hydroxylase deficiency,
 2355-2356
 Salty taste sensation, 212
 Salvinorin A (*Salvia divinorum*), 469e-4
¹⁵³Samarium therapy, 61, 103e-22, 119e-4, 474
 SAME. *See* Syndrome of apparent
 mineralocorticoid excess (SAME)
 Sand flea, 2750
 Sandfly
 in Carrión's disease, 1083
 in *Leishmania* infections, 1387, 1388t
 in pemphigus foliaceus, 371
 in Punta Toro virus disease, 1318
 in Toscana virus disease, 1318
 Sandfly fever, 152e-5t, 1310t, 1318
 Sandhoff's disease, 432e-1, 432e-3t, 2634t
 SANDO (sensory ataxic neuropathy and
 ophthalmoparesis), 451e-2t
 Sandostatin-LAR, 2271
 Sanfilippo syndromes, 432e-2t
 Sanjad-Sakati syndrome, 2483
 SA (sinoatrial) node, 273e-1, 1451, 1451f,
 1466-1467, 1466f
 SA (sinoatrial) node disease/dysfunction.
See Sinoatrial (SA) node disease/
 dysfunction
 SAPE (sentinel acute pancreatic event)
 hypothesis, 2098
 Saphenous vein bypass graft, 296e-2, 297e-3,
 297e-3f, 297e-3v, 1645
 SAPHO syndrome, 844, 2179
 SAPIEN valve, 296e-5, 297e-6f
 Sapovirus, 1286f, 1286t
 SAPS scoring systems, 1729